|  |
| --- |
|  |
| Book Name: | [Achievements and Challenges of Medicine and Medical Science](https://www.bookpi.org/bookstore/product/achievements-and-challenges-of-medicine-and-medical-science-vol-1/) |
| Manuscript Number: | **Ms\_BPR\_4503** |
| Title of the Manuscript:  | **Intercellular adhesion molecule-1 is a surrogate biomarker for subclinical atherosclerosis in Type 2 diabetes mellitus** |
| Type of the Article | **BOOK CHAPTER** |

|  |
| --- |
| PART 1: Comments |
|  | Reviewer’s comment**Artificial Intelligence (AI) generated or assisted review comments are strictly prohibited during peer review.** | Author’s Feedback *(Please correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)* |
| **Please write a few sentences regarding the importance of this manuscript for the scientific community. A minimum of 3-4 sentences may be required for this part.** | **This research investigates the potential of using ICAM-1 as a surrogate biomarker for subclinical atherosclerosis in patients with Type 2 Diabetes Mellitus (T2DM). This is important because early detection of atherosclerosis in this high-risk population could allow for timely intervention and potentially prevent cardiovascular events. The study's focus on ICAM-1 and its comparison with other potential markers like Ox-LDL and PTX-3 is particularly relevant.** |  |
| **Is the title of the article suitable?****(If not please suggest an alternative title)** | **The title, "Intercellular adhesion molecule-1 is a surrogate biomarker for subclinical atherosclerosis in Type 2 diabetes mellitus," is suitable and accurately reflects the study's primary focus and findings. It is concise, informative, and clearly conveys the main message of the research.** |  |
| Is the abstract of the article comprehensive? Do you suggest the addition (or deletion) of some points in this section? Please write your suggestions here. | **The abstract provides a good summary of the study's objectives, methods, results, and conclusions. It effectively highlights the key finding regarding ICAM-1 as a potential surrogate biomarker. However, it could benefit from slightly more specific information regarding the study population (e.g., mentioning the South Indian population) and the specific cutoff value identified for ICAM-1.** |  |
| **Is the manuscript scientifically, correct? Please write here.**  | **The manuscript appears to be scientifically sound. The methodology is well-described, including the selection criteria for participants, the measurement techniques for CIMT and biomarkers, and the statistical analyses employed. The results are presented clearly and are supported by the data. However, some minor points may require further clarification, such as a more in-depth discussion of the limitations of CIMT as a gold standard for subclinical atherosclerosis.** |  |
| **Are the references sufficient and recent? If you have suggestions of additional references, please mention them in the review form.****-** | **The references appear generally sufficient and recent, covering relevant background literature on atherosclerosis, T2DM, and the biomarkers investigated. However, a few more recent articles specifically addressing the role of ICAM-1 in subclinical atherosclerosis or its potential clinical utility as a surrogate marker could be included to further strengthen the discussion.** |  |
| Is the language/English quality of the article suitable for scholarly communications? | The language and English quality of the article are generally good. A thorough proofreading before final publication is recommended to catch any minor grammatical or phrasing issues. |  |
| Optional/General comments | The study provides valuable insights, but further discussion on the clinical implications of using ICAM-1 as a surrogate marker would be beneficial. Additionally, addressing potential confounding factors and limitations related to the study population and sample size would enhance the manuscript's impact. A comparative discussion of ICAM-1 with other established markers for cardiovascular risk in diabetic patients would also be valuable. |  |

|  |
| --- |
| **PART 2:**  |
|  | **Reviewer’s comment** | **Author’s comment** *(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)* |
| **Are there ethical issues in this manuscript?**  | *(If yes, Kindly please write down the ethical issues here in details)* |  |

|  |
| --- |
| **Reviewer Details:** |
| Name: | **Hamza Chaudhary** |
| Department, University & Country | **King Edward Medical University, Pakistan** |